Campaign News
Landmark study offering new hope for the treatment of people living with peanut allergies
Allergies are commonly believed to have no cure. Given a large percentage of the population experiences various allergies, with peanut allergy the number one cause of allergy-induced fatalities, it was only a matter of time before scientists chose to explore ways to treat the serious health problem. Aimmune Therapeutics-funded study (PALISADE) involved almost 500 participants…
Read MoreFive take home lessons from the immune system
There are many lessons we can learn from the many efficient and well-orchestrated systems of the human body. Cell differentiation occurs very early on in the development of the human embryo, allowing for cells to perform highly specialised functions. The immune system serves as a wonderful analogy of how cell specialisation, collaboration, team work, diversity…
Read MoreVIVA! Communications external planning workshop 2019
Team VIVA! set off early Thursday, January 17, for our annual workshop at Lilianfels Blue Mountains Resort & Spa, positioned at the edge of Echo Point, in the picturesque town of Katoomba. We arrived ready to begin what would prove an intensive two-day learning experience, capped off with fantastic food, a touch of wine and…
Read MoreTips for beating the heat
In the heat of summer, it’s important to make sure you’re taking extra good care of your health, especially on the scorching hot days. Too much sun can not only be detrimental to your skin, but can cause heatstroke and in the worst instance, death. These are crucial steps all Australians can take to lower…
Read MoreAustralian-developed coeliac disease vaccine fast-tracked by the FDA
A vaccine for coeliac disease could soon be made available with the Australian-developed immunisation gaining fast-track designation from America’s Food and Drug Administration. ImmusanT’s Nexvax2, developed at the Walter and Eliza Hall Institute (WEHI) in Victoria, is set for a prompt review at the completion of its trial phases. Currently phase two, involving 150 patients…
Read More